186
Participants
Start Date
December 13, 2018
Primary Completion Date
March 14, 2025
Study Completion Date
January 15, 2026
EMB-01
"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
RECRUITING
Gabrail Cancer Center Research, Canton
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
Shanghai Chest Hosptial, Shanghai
RECRUITING
Guangdong General Hospital, Guangzhou
RECRUITING
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Covance
INDUSTRY
Shanghai EpimAb Biotherapeutics Co., Ltd.
INDUSTRY